FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308183658> ?p ?o ?g. }

• W4308183658 endingPage "550" @default.
• W4308183658 startingPage "535" @default.
• W4308183658 abstract "Glucagon receptor (GCGR) antagonism ameliorates hyperglycaemia and promotes beta cell regeneration in mouse models of type 2 diabetes. However, the underlying mechanisms remain unclear. The present study aimed to investigate the mechanism of beta cell regeneration induced by GCGR antagonism in mice.The db/db mice and high-fat diet (HFD)+streptozotocin (STZ)-induced mice with type 2 diabetes were treated with antagonistic GCGR monoclonal antibody (mAb), and the metabolic variables and islet cell quantification were evaluated. Plasma cytokine array and liver RNA sequencing data were used to screen possible mediators, including fibroblast growth factor 21 (FGF21). ELISA, quantitative RT-PCR and western blot were applied to verify FGF21 change. Blockage of FGF21 signalling by FGF21-neutralising antibody (nAb) was used to clarify whether FGF21 was involved in the effects of GCGR mAb on the expression of beta cell identity-related genes under plasma-conditional culture and hepatocyte co-culture conditions. FGF21 nAb-treated db/db mice, systemic Fgf21-knockout (Fgf21-/-) diabetic mice and hepatocyte-specific Fgf21-knockout (Fgf21Hep-/-) diabetic mice were used to reveal the involvement of FGF21 in beta cell regeneration. A BrdU tracing study was used to analyse beta cell proliferation in diabetic mice treated with GCGR mAb.GCGR mAb treatment improved blood glucose control, and increased islet number (db/db 1.6±0.1 vs 0.8±0.1 per mm2, p<0.001; HFD+STZ 1.2±0.1 vs 0.5±0.1 per mm2, p<0.01) and area (db/db 2.5±0.2 vs 1.2±0.2%, p<0.001; HFD+STZ 1.0±0.1 vs 0.3±0.1%, p<0.01) in diabetic mice. The plasma cytokine array and liver RNA sequencing data showed that FGF21 levels in plasma and liver were upregulated by GCGR antagonism. The GCGR mAb induced upregulation of plasma FGF21 levels (db/db 661.5±40.0 vs 466.2±55.7 pg/ml, p<0.05; HFD+STZ 877.0±106.8 vs 445.5±54.0 pg/ml, p<0.05) and the liver levels of Fgf21 mRNA (db/db 3.2±0.5 vs 1.8±0.1, p<0.05; HFD+STZ 2.0±0.3 vs 1.0±0.2, p<0.05) and protein (db/db 2.0±0.2 vs 1.4±0.1, p<0.05; HFD+STZ 1.6±0.1 vs 1.0±0.1, p<0.01). Exposure to plasma or hepatocytes from the GCGR mAb-treated mice upregulated the mRNA levels of characteristic genes associated with beta cell identity in cultured mouse islets and a beta cell line, and blockage of FGF21 activity by an FGF21 nAb diminished this upregulation. Notably, the effects of increased beta cell number induced by GCGR mAb were attenuated in FGF21 nAb-treated db/db mice, Fgf21-/- diabetic mice and Fgf21Hep-/- diabetic mice. Moreover, GCGR mAb treatment enhanced beta cell proliferation in the two groups of diabetic mice, and this effect was weakened in Fgf21-/- and Fgf21Hep-/- mice.Our findings demonstrate that liver-derived FGF21 is involved in the GCGR antagonism-induced beta cell regeneration in a mouse model of type 2 diabetes." @default.
• W4308183658 created "2022-11-09" @default.
• W4308183658 creator A5003572126 @default.
• W4308183658 creator A5006301048 @default.
• W4308183658 creator A5013373738 @default.
• W4308183658 creator A5019872937 @default.
• W4308183658 creator A5025015130 @default.
• W4308183658 creator A5027463348 @default.
• W4308183658 creator A5044599081 @default.
• W4308183658 creator A5049882309 @default.
• W4308183658 creator A5050887292 @default.
• W4308183658 creator A5062488095 @default.
• W4308183658 creator A5081329695 @default.
• W4308183658 creator A5082841726 @default.
• W4308183658 date "2022-11-04" @default.
• W4308183658 modified "2023-10-14" @default.
• W4308183658 title "Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes" @default.
• W4308183658 cites W1573089314 @default.
• W4308183658 cites W1592686897 @default.
• W4308183658 cites W2000665430 @default.
• W4308183658 cites W2001391476 @default.
• W4308183658 cites W2003946536 @default.
• W4308183658 cites W2004014076 @default.
• W4308183658 cites W2041739600 @default.
• W4308183658 cites W2055172928 @default.
• W4308183658 cites W2069279764 @default.
• W4308183658 cites W2095995901 @default.
• W4308183658 cites W2112871433 @default.
• W4308183658 cites W2121049950 @default.
• W4308183658 cites W2127167047 @default.
• W4308183658 cites W2130375490 @default.
• W4308183658 cites W2130700195 @default.
• W4308183658 cites W2156888164 @default.
• W4308183658 cites W2169046916 @default.
• W4308183658 cites W2296260051 @default.
• W4308183658 cites W2342578893 @default.
• W4308183658 cites W2579298009 @default.
• W4308183658 cites W2605119706 @default.
• W4308183658 cites W2620406790 @default.
• W4308183658 cites W2622785186 @default.
• W4308183658 cites W2738821725 @default.
• W4308183658 cites W2740692193 @default.
• W4308183658 cites W2762892866 @default.
• W4308183658 cites W2779666226 @default.
• W4308183658 cites W2781547740 @default.
• W4308183658 cites W2893215169 @default.
• W4308183658 cites W2900050340 @default.
• W4308183658 cites W2900577900 @default.
• W4308183658 cites W2944658035 @default.
• W4308183658 cites W2947644232 @default.
• W4308183658 cites W2956163181 @default.
• W4308183658 cites W2980465217 @default.
• W4308183658 cites W2981706918 @default.
• W4308183658 cites W3009177262 @default.
• W4308183658 cites W3020528808 @default.
• W4308183658 cites W3036043714 @default.
• W4308183658 cites W3044716505 @default.
• W4308183658 cites W3085056884 @default.
• W4308183658 cites W3130443851 @default.
• W4308183658 cites W4281947100 @default.
• W4308183658 doi "https://doi.org/10.1007/s00125-022-05822-2" @default.
• W4308183658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331598" @default.
• W4308183658 hasPublicationYear "2022" @default.
• W4308183658 type Work @default.
• W4308183658 citedByCount "6" @default.
• W4308183658 countsByYear W43081836582023 @default.
• W4308183658 crossrefType "journal-article" @default.
• W4308183658 hasAuthorship W4308183658A5003572126 @default.
• W4308183658 hasAuthorship W4308183658A5006301048 @default.
• W4308183658 hasAuthorship W4308183658A5013373738 @default.
• W4308183658 hasAuthorship W4308183658A5019872937 @default.
• W4308183658 hasAuthorship W4308183658A5025015130 @default.
• W4308183658 hasAuthorship W4308183658A5027463348 @default.
• W4308183658 hasAuthorship W4308183658A5044599081 @default.
• W4308183658 hasAuthorship W4308183658A5049882309 @default.
• W4308183658 hasAuthorship W4308183658A5050887292 @default.
• W4308183658 hasAuthorship W4308183658A5062488095 @default.
• W4308183658 hasAuthorship W4308183658A5081329695 @default.
• W4308183658 hasAuthorship W4308183658A5082841726 @default.
• W4308183658 hasBestOaLocation W43081836581 @default.
• W4308183658 hasConcept C106646824 @default.
• W4308183658 hasConcept C126322002 @default.
• W4308183658 hasConcept C134018914 @default.
• W4308183658 hasConcept C165220095 @default.
• W4308183658 hasConcept C170493617 @default.
• W4308183658 hasConcept C202751555 @default.
• W4308183658 hasConcept C2776200302 @default.
• W4308183658 hasConcept C2776398474 @default.
• W4308183658 hasConcept C2776828364 @default.
• W4308183658 hasConcept C2777180221 @default.
• W4308183658 hasConcept C2778542361 @default.
• W4308183658 hasConcept C2778563252 @default.
• W4308183658 hasConcept C2779280383 @default.
• W4308183658 hasConcept C2779306644 @default.
• W4308183658 hasConcept C55493867 @default.
• W4308183658 hasConcept C555293320 @default.
• W4308183658 hasConcept C71924100 @default.
• W4308183658 hasConcept C74373430 @default.

• next